Company Overview of Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing neuropsychiatric therapeutics. It is developing ganaxolone, a small molecule, which is in Phase III clinical trials to treat patients with refractory focal onset seizures; and is in Phase II clinical trials for the treatment of orphan disease, as well as is in Phase II crossover clinical study to treat behaviors in Fragile X Syndrome, an orphan indication. The company is also developing an IV formulation for use in the hospital setting to control acute seizures. It has a collaboration agreement with NovaMedica, LLC; and license agreement with Purdue Neuroscience Company. Marin...
100 Matsonford Road
Three Radnor Corporate Center
Radnor, PA 19087
Founded in 2003
Key Executives for Marinus Pharmaceuticals, Inc.
Executive Chairman, Chief Executive Officer and President
Total Annual Compensation: $455.0K
Chief Financial Officer, Vice President, Treasurer and Secretary
Total Annual Compensation: $405.0K
Compensation as of Fiscal Year 2014.
Marinus Pharmaceuticals, Inc. Key Developments
Marinus Pharmaceuticals Completes Patient Recruitment in Phase 3 Clinical Trial of Ganaxolone in Focal Onset Seizures
Dec 16 15
Marinus Pharmaceuticals, Inc. announced that it has completed patient recruitment for the Phase 3 clinical trial of ganaxolone, a CNS-selective GABAA modulator, in adults with drug-resistant focal onset seizures. Sites participating in this global study have completed screening patients. After establishing eight weeks of baseline seizure frequency, patients randomized in the study undergo a two-week titration period followed by a twelve-week maintenance period. The company anticipates announcing top-line results from the study in mid-2016. The global, randomized, placebo-controlled Phase 3 study is designed to evaluate the effectiveness and safety of ganaxolone as an adjunctive therapy in adults with drug-resistant focal onset seizures. Approximately 350 patients will be randomized to receive either 1,800 mg/day of ganaxolone or placebo for 12 weeks. The primary endpoint of the study is percent change in seizure frequency per 28 days relative to the baseline. Further information about the Phase 3 study can be found on ClinicalTrials.gov, using Identifier NCT01963208.
Marinus Pharmaceuticals, Inc. Announces Executive Appointments
Dec 3 15
Marinus Pharmaceuticals, Inc. announced the hiring of Jaakko Lappalainen, M.D., Ph.D., as Vice President of Clinical Development and Kimberly A. McCormick, PharmD, as Head of Regulatory Affairs. Both individuals will report to the company’s Chief Medical Officer, Albena Patroneva, M.D. Dr. Lappalainen is a U.S. board certified psychiatrist with extensive experience in clinical practice and medical research. Most recently, Lappalainen served as Executive Director, Drug Development Services at Premier Research CRO, where he oversaw the safety and medical monitoring of clinical trials and provided consultations on clinical trial design and drug development. Most recently, McCormick served as Senior Director, Global Regulatory Affairs, Lifitegrast and ADHD/Vyvanse New Uses for Shire Pharmaceuticals.
Marinus Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2015, Nov-17-2015 08:00 AM
Nov 12 15
Marinus Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2015, Nov-17-2015 08:00 AM. Venue: The New York Palace Hotel, Hubbard Room, New York, New York, United States. Speakers: Christopher Michael Cashman, Executive Chairman, Chief Executive Officer and President.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|